PL354604A1 - Process for the preparation of amorphous atorvastatin calcium - Google Patents

Process for the preparation of amorphous atorvastatin calcium

Info

Publication number
PL354604A1
PL354604A1 PL00354604A PL35460400A PL354604A1 PL 354604 A1 PL354604 A1 PL 354604A1 PL 00354604 A PL00354604 A PL 00354604A PL 35460400 A PL35460400 A PL 35460400A PL 354604 A1 PL354604 A1 PL 354604A1
Authority
PL
Poland
Prior art keywords
atorvastatin calcium
amorphous atorvastatin
preparation
amorphous
crude
Prior art date
Application number
PL00354604A
Other languages
English (en)
Polish (pl)
Inventor
Zoltan Greff
Nagy Peter Kotay
Jozsef Barkoczy
Gyula Simig
Laszlo Balazs
Imre Doman
Zoltan Ratkai
Peter Seres
Kirallyi Zsuzsa Szent
Ferenc Bartha
Donath Gyorgyi Vereczkeyne
Kalman Nagy
Original Assignee
Egis Gyogyszergyar Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Rt. filed Critical Egis Gyogyszergyar Rt.
Publication of PL354604A1 publication Critical patent/PL354604A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL00354604A 1999-10-18 2000-10-17 Process for the preparation of amorphous atorvastatin calcium PL354604A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9903634A HU226640B1 (en) 1999-10-18 1999-10-18 Process for producing amorphous atorvastatin calcium salt
PCT/HU2000/000106 WO2001028999A1 (en) 1999-10-18 2000-10-17 Process for the preparation of amorphous atorvastatin calcium

Publications (1)

Publication Number Publication Date
PL354604A1 true PL354604A1 (en) 2004-01-26

Family

ID=90014241

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354604A PL354604A1 (en) 1999-10-18 2000-10-17 Process for the preparation of amorphous atorvastatin calcium

Country Status (17)

Country Link
EP (1) EP1235800B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003512354A (cg-RX-API-DMAC7.html)
KR (1) KR100664353B1 (cg-RX-API-DMAC7.html)
CN (1) CN1157374C (cg-RX-API-DMAC7.html)
AT (1) ATE345327T1 (cg-RX-API-DMAC7.html)
AU (1) AU1166301A (cg-RX-API-DMAC7.html)
CA (1) CA2388018C (cg-RX-API-DMAC7.html)
CZ (1) CZ300071B6 (cg-RX-API-DMAC7.html)
DE (1) DE60031882T2 (cg-RX-API-DMAC7.html)
HR (1) HRP20020334B1 (cg-RX-API-DMAC7.html)
HU (1) HU226640B1 (cg-RX-API-DMAC7.html)
PL (1) PL354604A1 (cg-RX-API-DMAC7.html)
RS (1) RS50473B (cg-RX-API-DMAC7.html)
RU (1) RU2255932C2 (cg-RX-API-DMAC7.html)
SK (1) SK286861B6 (cg-RX-API-DMAC7.html)
UA (1) UA72777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001028999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
DE10135493A1 (de) * 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
AU2002255479B2 (en) 2001-07-30 2008-09-11 Dr. Reddy's Laboratories Ltd. Crystalline forms VI and VII of atorvastatin clacium
HUP0500074A3 (en) * 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CN1692906A (zh) * 2004-04-30 2005-11-09 鲁南制药集团股份有限公司 治疗高血脂症的组合物
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006037125A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
CN101039906A (zh) * 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same

Also Published As

Publication number Publication date
HUP9903634A3 (en) 2002-01-28
RU2255932C2 (ru) 2005-07-10
RS50473B (sr) 2010-03-02
HU226640B1 (en) 2009-05-28
YU28302A (sh) 2005-06-10
CA2388018C (en) 2008-04-08
ATE345327T1 (de) 2006-12-15
EP1235800A1 (en) 2002-09-04
CA2388018A1 (en) 2001-04-26
CN1379760A (zh) 2002-11-13
HUP9903634D0 (en) 1999-12-28
DE60031882T2 (de) 2007-07-05
SK5192002A3 (en) 2002-11-06
WO2001028999A1 (en) 2001-04-26
CN1157374C (zh) 2004-07-14
KR20020063166A (ko) 2002-08-01
AU1166301A (en) 2001-04-30
HUP9903634A2 (hu) 2001-12-28
DE60031882D1 (de) 2006-12-28
HK1050199A1 (en) 2003-06-13
HRP20020334A2 (en) 2004-02-29
HRP20020334B1 (hr) 2007-12-31
JP2003512354A (ja) 2003-04-02
SK286861B6 (sk) 2009-06-05
UA72777C2 (en) 2005-04-15
KR100664353B1 (ko) 2007-01-02
EP1235800B1 (en) 2006-11-15
CZ20021256A3 (cs) 2002-08-14
CZ300071B6 (cs) 2009-01-21

Similar Documents

Publication Publication Date Title
YU28302A (sh) Postupak za pripremanje amorfnog atorvastatin-kalcijuma
Short et al. A solid-phase combinatorial method for the synthesis of novel 5-and 6-membered ring lactams
MY133511A (en) Process for the production of amorphous atorvastatin calcium
ATE243672T1 (de) Neue thyroid-rezeptorliganden und verfahren
Artamonov et al. Synthesis of isomeric 6-trifluoromethyl-3-azabicyclo [3.1. 0] hexanes: Conformationally restricted analogues of 4-trifluoromethylpiperidine
IL130338A0 (en) Pyrroles as sPLA2 inhibitors
JP2003512354A5 (cg-RX-API-DMAC7.html)
YU23499A (sh) Inhibitorski amidi apo-b-sekrecije/mtp-a
SE1102739T3 (cg-RX-API-DMAC7.html)
Liu et al. A mild method for ring-opening aminolysis of lactones
GR3025420T3 (en) Process for solid support nucleic acid synthesis and compounds useful as solid supports in said process
US6646133B1 (en) Process for the preparation of amorphous atorvastatin calcium
Barker et al. A high yielding synthesis of anthranilate esters from sterically hindered alcohols
Cerreti et al. A novel synthesis of tricyclic-fused hydrindene–azetidinone compounds by sequential Mn (III)-promoted 4-exo-trig cyclization/radical aromatic substitution
AU668161B2 (en) Novel process and intermediates
Vatèle One-pot selective cleavage of prenyl carbamates using iodine in methanol followed by zinc
Hoffmann et al. Bioconversion of grindelic acid into 3α-hydroxygrindelic acid
Delle Monache et al. Iodolactonization of 3-amino-4-pentenoic acid: a stereoselective synthesis of syn-γ-hydroxy-β-amino acids
LluisaáBennasar A new synthetic entry to the alkaloids of the mavacurine group. First total synthesis of (▒)-2, 7-dihydropleiocarpamine
US20040063969A1 (en) Process for the preparation of amorphous atorvastatin calcium
Pernfa Stabilisation of a Cis Amide Bond in a Host-Guest Complex. Glen J. Pernfa, Jeremy D. Kilburn, Jonathan W. Essex, Russell J. Mortishire-Smith, and Michael Rowley
Tantry et al. Microwave accelerated efficient synthesis of N-fluorenylmethoxycarbonyl/t-butoxycarbonyl/benzyloxycarbonyl-5-oxazolidinones
김건철 et al. An Efficient Transformation to the Structure of (±)-Supinidine
IE85318B1 (en) (R-(R*R*))-2-(4-fluorophenyl)-á,d-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
PL177187B1 (pl) 2,3,4,3’,4’-penta -O-benzylo-sacharoza i sposób jej otrzymywania

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)